Bollard Group LLC Decreases Stock Holdings in Aclaris Therapeutics, Inc. $ACRS

Bollard Group LLC lowered its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 34.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 804,445 shares of the biotechnology company’s stock after selling 421,031 shares during the quarter. Bollard Group LLC’s holdings in Aclaris Therapeutics were worth $2,421,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Invesco Ltd. raised its position in shares of Aclaris Therapeutics by 409.0% during the 1st quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 45,864 shares in the last quarter. Millennium Management LLC grew its position in Aclaris Therapeutics by 111.0% in the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock worth $6,325,000 after acquiring an additional 2,175,101 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Aclaris Therapeutics by 29.7% in the first quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company’s stock worth $851,000 after acquiring an additional 127,366 shares in the last quarter. Geode Capital Management LLC increased its stake in Aclaris Therapeutics by 108.4% during the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock worth $3,501,000 after acquiring an additional 1,282,042 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Aclaris Therapeutics by 25.1% during the second quarter. JPMorgan Chase & Co. now owns 623,792 shares of the biotechnology company’s stock worth $886,000 after acquiring an additional 125,071 shares during the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ACRS shares. Guggenheim initiated coverage on Aclaris Therapeutics in a research note on Tuesday, May 5th. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Friday, March 27th. UBS Group set a $10.00 price target on Aclaris Therapeutics in a report on Thursday, April 16th. Piper Sandler raised their price target on Aclaris Therapeutics from $7.00 to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Finally, Wedbush lifted their price objective on shares of Aclaris Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $11.50.

Insider Activity at Aclaris Therapeutics

In other news, major shareholder Braden Michael Leonard sold 300,000 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total transaction of $1,359,000.00. Following the transaction, the insider owned 13,950,000 shares of the company’s stock, valued at approximately $63,193,500. This represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.80% of the company’s stock.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $4.32 on Friday. Aclaris Therapeutics, Inc. has a 1-year low of $1.34 and a 1-year high of $5.15. The firm has a market capitalization of $603.35 million, a P/E ratio of -7.71 and a beta of 0.76. The company’s 50-day moving average is $4.39 and its 200 day moving average is $3.66.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 832.58% and a negative return on equity of 55.89%. The business had revenue of $2.00 million during the quarter, compared to the consensus estimate of $1.32 million. Research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.